These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Understanding the concepts in urologic oncology]. Rübben H Urologe A; 1987 Jan; 26(1):1. PubMed ID: 3576858 [No Abstract] [Full Text] [Related]
9. [Biochemical modulation of chemotherapy of urologic malignancies]. Okada K Hinyokika Kiyo; 1993 Dec; 39(12):1195-6. PubMed ID: 8285170 [TBL] [Abstract][Full Text] [Related]
10. [Interdisciplinary urologic oncology]. Meran JG; Schramek P Wien Med Wochenschr; 2008; 158(11-12):299. PubMed ID: 18641928 [No Abstract] [Full Text] [Related]
11. Bio-immunotherapy for cancer in experimental studies and clinical application: current status and future challenges. Shen RN; Lu L; Kaiser HE; Broxmeyer HE In Vivo; 1994; 8(5):643-52. PubMed ID: 7727711 [TBL] [Abstract][Full Text] [Related]
12. Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. Khawli LA; Hu P; Epstein AL Handb Exp Pharmacol; 2008; (181):291-328. PubMed ID: 18071951 [TBL] [Abstract][Full Text] [Related]
13. [Interferon therapy in urology]. Kriegmair M; Hofstetter A Urologe A; 1989 Mar; 28(2):116-21. PubMed ID: 2470188 [TBL] [Abstract][Full Text] [Related]
14. Does chemotherapy augment anti-tumor immunotherapy by preferential impairment of regulatory T cells? Zhang L; Dermawan KT; Jin ML; Xiong SD; Chu YW Med Hypotheses; 2008 Nov; 71(5):802-4. PubMed ID: 18691831 [TBL] [Abstract][Full Text] [Related]
15. Cytoreductive nephrectomy in metastatic renal cell carcinoma: the evolving role of surgery in the era of molecular targeted therapy. Kwan KG; Kapoor A Curr Opin Support Palliat Care; 2009 Sep; 3(3):157-65. PubMed ID: 19528804 [TBL] [Abstract][Full Text] [Related]
17. Open clinical uro-oncology trials in Canada. Mackenzie MJ; Rodrigues G; Winquist E Can J Urol; 2009 Dec; 16(6):4964-70. PubMed ID: 20003683 [No Abstract] [Full Text] [Related]
18. [Monoclonal anti-idiotype antibodies in immunotherapy of ovarian carcinoma (MAb ACA125) and breast carcinoma (MAb ACA14C5)]. Wagner U; Köhler S; Prietl G; Giffels P; Schmidt-Nicolai S; Schlebusch H; Grünn U; Bender H; Biersack HJ; De Potter C; Krebs D; Wallwiener D Zentralbl Gynakol; 1999; 121(4):190-5. PubMed ID: 10355096 [TBL] [Abstract][Full Text] [Related]
19. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines. Ruffini PA; Neelapu SS; Kwak LW; Biragyn A Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812 [TBL] [Abstract][Full Text] [Related]
20. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy. Hwang C; Sanda MG Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]